Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19

<p><strong>Importance</strong> Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support.<...

Täydet tiedot

Bibliografiset tiedot
Päätekijät:	WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, JAC, Murthy, S, Diaz, JV, Slutsky, AS, Villar, J, Angus, DC, Annane, D, Azevedo, LCP, Berwanger, O, Cavalcanti, AB, Dequin, P-F, Du, B, Emberson, J, Fisher, D, Giraudeau, B, Gordon, AC, Granholm, A, Green, C, Haynes, R, Heming, N, Higgins, JPT, Horby, P, Jüni, P, Landray, MJ, Le Gouge, A, Leclerc, M, Lim, WS, Machado, FR, McArthur, C, Meziani, F, Møller, MH, Perner, A, Petersen, MW, Savovic, J, Tomazini, B, Veiga, VC, Webb, S, Marshall, JC
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	American Medical Association 2020

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19

Samankaltaisia teoksia